Abuse-Deterrent Oxycodone Receives FDA Approval

A new abuse-deterrent formulation of oxycodone, an opioid pain killer, has received approval from the U.S. Food and Drug Administration. Collegium Pharmaceuticals on April 26 announced the FDA approval of its Xtampza ER, an extended-release medication intended for pain that requires daily, around-the-clock treatment. The company said Xtampza is its first product using the proprietary Deterx technology to deter abuse. The drug can be crushed or chewed without circumventing its extended-release formulation. Collegium said it plans to launch Xtampza ER in the U.S. in mid-2016, with five streng...